RP9 Inhibitors
RP9 inhibitors belong to a specialized category of chemical agents that interact with a specific protein known as RP9. The RP9 protein is a component of a larger biological pathway, where it typically plays a crucial role in the normal functioning and regulation of various cellular processes. Inhibitors targeting RP9 are designed to modulate the activity of this protein through a direct interaction, which can result in an alteration of its natural behavior within the cell. These compounds are characterized by their ability to bind to the RP9 protein, affecting its conformation, stability, or its interactions with other cellular components. The design of RP9 inhibitors is a sophisticated process that requires an in-depth understanding of the protein's structure and the molecular dynamics that govern its function. Researchers utilize techniques such as high-throughput screening, computational modeling, and medicinal chemistry to identify and optimize these inhibitors for high affinity and specificity to the RP9 protein.
The development and study of RP9 inhibitors are rooted in the realm of biochemistry and molecular biology, where the focus lies on unraveling the mechanisms by which these molecules exert their influence on RP9. The binding of these inhibitors to the RP9 protein can be reversible or irreversible, depending on the nature of the inhibitor and the type of interaction it forms with the protein. Reversible inhibitors typically form non-covalent bonds with the protein, allowing for temporary modulation, while irreversible inhibitors form covalent bonds, leading to permanent modification of the protein. The study of RP9 inhibitors also encompasses the exploration of their physicochemical properties, such as solubility, stability, and their ability to cross cellular membranes. These properties are critical in understanding how these inhibitors interact with the RP9 protein within the complex environment of a cell. Investigations into the molecular interactions between RP9 inhibitors and the RP9 protein also involve examining the kinetics of inhibitor binding, which provides insights into the rate at which these events occur and the eventual impact on the protein's function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway. By blocking PI3K, it inhibits the downstream Akt signaling which could be crucial for the post-translational modification or localization of RP9, thereby reducing its functional activity. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporine A is an immunosuppressant that binds to the cyclophilins and inhibits calcineurin. By inhibiting calcineurin, Cyclosporine A can disrupt NFAT (Nuclear Factor of Activated T-cells) translocation to the nucleus. If RP9 activity is regulated by NFAT-mediated transcriptional events, this would lead to a decrease in RP9 functional activity. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor. Aurora kinase A is involved in cell cycle progression, and its inhibition can lead to disrupted cell cycle and potential impacts on protein expression levels. If RP9 function is linked to cell cycle-dependent signaling or expression, inhibition by Alisertib could result in reduced activity of RP9. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, which can lead to the downregulation of protein synthesis pathways. If RP9 synthesis is mTOR-dependent, Rapamycin would decrease the functional activity of RP9 by reducing its synthesis levels. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2 which blocks the MAPK/ERK pathway. By inhibiting this pathway, U0126 could prevent the phosphorylation and activation of proteins that may be essential for RP9 activity or localization, thereby decreasing the functional activity of RP9. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor leading to the depletion of calcium stores in the endoplasmic reticulum. If RP9 activity is dependent on calcium signaling, the disruption caused by Thapsigargin could lead to decreased activation or functionality of RP9. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor, which can lead to the accumulation of misfolded proteins and disrupt cellular proteostasis. If RP9 requires proteasome activity for its degradation or functional regulation, MG132 could indirectly reduce the functional activity of RP9 by affecting the degradation pathway. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A inhibits protein transport from the endoplasmic reticulum to the Golgi apparatus. If the proper functioning or maturation of RP9 involves this transport pathway, Brefeldin A could decrease RP9 activity by preventing its proper localization or post-translational modification. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a potent inhibitor of protein kinase C (PKC). If RP9 is activated or modulated by PKC-mediated phosphorylation, inhibition by Chelerythrine would lead to decreased functional activity of RP9. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. By inhibiting p38 MAP kinase, it can disrupt stress-responsive cellular pathways. If RP9 plays a role in these pathways or its stability is influenced by p38 MAPK-mediated signaling, SB203580 could reduce the activity of RP9. | ||||||